Neuroimmunology News and Research

RSS

Cytokine GM-CSF likely plays important role in MS

Multiple sclerosis (MS) is caused by immune cells that activate a cascade of chemicals in the brain, attacking and degrading the insulation that keeps neuronal signals moving. These chemicals, called cytokines, drive the inflammation in the brain, attracting more immune cells, and causing the debilitating disease marked by loss of neurological function.

30 Apr 2015

Antibodies may trigger psychiatric illness in children

A world first study revealing the presence of two antibodies in a sub-group of children experiencing their first episode of psychosis affirms a longstanding recognition that auto-immune disorders play a significant role in psychiatric illness.

31 Mar 2015

Better interventions possible for children experiencing acute psychosis with antibodies

Antibodies defend the body against bacterial, viral, and other invaders. But sometimes the body makes antibodies that attack healthy cells. In these cases, autoimmune disorders develop.

6 Mar 2015

Expert panel makes new sleep-time recommendations

Loyola University Chicago Stritch School of Medicine researcher Lydia DonCarlos, PhD, is a member of an expert panel that's making new recommendations on how much sleep people need.

12 Feb 2015

Researchers document pathological progress of multiple sclerosis

The Centre for Brain Research at the MedUni Vienna is regarded as a world leader in researching the mechanisms involved with multiple sclerosis (MS). Now, in a paper published in the highly respected journal Lancet Neurology, an international team of researchers from Edinburgh, Cleveland and Vienna, under the leadership of Hans Lassmann, Head of the Department of Neuroimmunology at the MedUni Vienna, has for the first time documented the pathological progress of the disease from its early to late stage and also shown that inflammatory and neurodegenerative processes have a role to play.

9 Feb 2015

Griffith researcher awarded $1.85m grant to accelerate diagnosis, treatment for CFS

Providing increased services for Chronic Fatigue Syndrome sufferers will be the focus of Griffith research following the award of a $1.85m grant to one of Australia’s foremost authorities on the condition.

14 Oct 2014

New MS treatment found safe, tolerable in phase I clinical trials

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal.

28 Aug 2014

New specialised clinic, smartphone app aim to improve health outcomes of chronic fatigue patients

Sufferers of Chronic Fatigue Syndrome are set to benefit with the dual launch of a specialist Griffith University clinic and smartphone app, both aimed to manage their illness and improve health outcomes.

29 Jul 2014

Noninvasive optical imaging device helps to detect changes linked with Alzheimer's disease

A noninvasive optical imaging device developed at Cedars-Sinai can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer's disease, according to preliminary results from investigators conducting a clinical trial in Australia.

14 Jul 2014

Scientists report first successful step toward vaccine that targets mutation in brain cancer

Astrocytomas and oligodendrogliomas are subtypes of a brain cancer called 'glioma'. These incurable brain tumors arise from glial cells, a type of support cell found in the central nervous system.

26 Jun 2014

People with CFS to benefit from Griffith’s National Centre for Neuroimmunology and Emerging Diseases

People living with chronic fatigue are set to benefit with the opening next week (Dec 2), of the National Centre for Neuroimmunology and Emerging Diseases at Griffith University.

30 Nov 2013

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.

12 Nov 2013

Publication provides update on the origins and causes of anxiety disorders

Anxiety disorders are not uncommon and are often 'comorbid' with other forms of mental disorders. This publication provides an update on the origins and the causes of anxiety disorders and their related symptoms.

8 Oct 2013

Biochemists discover promising vitamin D-based treatment that halts or reverse MS

A diagnosis of multiple sclerosis (MS) is a hard lot. Patients typically get the diagnosis around age 30 after experiencing a series of neurological problems such as blurry vision, wobbly gait or a numb foot. From there, this neurodegenerative disease follows an unforgiving course.

1 Oct 2013

Biochemists discover promising vitamin D-based treatment that can halt MS

A diagnosis of multiple sclerosis is a hard lot. Patients typically get the diagnosis around age 30 after experiencing a series of neurological problems such as blurry vision, wobbly gait or a numb foot. From there, this neurodegenerative disease follows an unforgiving course.

29 Sep 2013

LMU immunologists develop new technique to fight against tumors, autoimmune diseases

Immunologists at Ludwig-Maximilians-Universitaet (LMU) in Munich have come up with a new technique that can be used both to fight tumors and to treat autoimmune diseases. A new grant from the Federal Ministry for Education and Research will enable the method to be developed further.

14 Aug 2013

Neuroimmunology News and Research

Cytokine GM-CSF likely plays important role in MS

Antibodies may trigger psychiatric illness in children

Better interventions possible for children experiencing acute psychosis with antibodies

Expert panel makes new sleep-time recommendations

Researchers document pathological progress of multiple sclerosis

Griffith researcher awarded $1.85m grant to accelerate diagnosis, treatment for CFS

New MS treatment found safe, tolerable in phase I clinical trials

New specialised clinic, smartphone app aim to improve health outcomes of chronic fatigue patients

Noninvasive optical imaging device helps to detect changes linked with Alzheimer's disease

Scientists report first successful step toward vaccine that targets mutation in brain cancer

People with CFS to benefit from Griffith’s National Centre for Neuroimmunology and Emerging Diseases

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

Publication provides update on the origins and causes of anxiety disorders

Biochemists discover promising vitamin D-based treatment that halts or reverse MS

Biochemists discover promising vitamin D-based treatment that can halt MS

LMU immunologists develop new technique to fight against tumors, autoimmune diseases

Argentina's ANMAT approves AUBAGIO for patients with relapsing multiple sclerosis

Study reveals increased dietary salt intake may lead to autoimmune disorders

NSU-COM to hold grand opening for America's first Institute for Neuro Immune Medicine

Myasthenia gravis therapies: an interview with Professor Daniel Drachman

Immunology eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News